NYSEAMERICAN:CLDI Calidi Biotherapeutics Q2 2026 Earnings Report $1.08 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.08 +0.00 (+0.46%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings History Calidi Biotherapeutics EPS ResultsActual EPS-$2.94Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACalidi Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACalidi Biotherapeutics Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Calidi Biotherapeutics Earnings HeadlinesCalidi Put On Notice By NYSE For Non-Compliance In Stockholders' Equity; Shares Fall By 5%September 26, 2026 | rttnews.comCalidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity DeficiencySeptember 25, 2026 | markets.businessinsider.comThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.October 2 at 1:00 AM | Chaikin Analytics (Ad)Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity DeficiencySeptember 25, 2026 | globenewswire.comCalidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Price Down 1.8% - Should You Sell?September 24, 2026 | americanbankingnews.comCalidi Biotherapeutics Announces Registered Direct Stock OfferingSeptember 22, 2026 | tipranks.comSee More Calidi Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email. Email Address About Calidi BiotherapeuticsCalidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company developing stem cell-based therapies designed to improve the delivery and effectiveness of cancer treatments. The company’s approach uses allogeneic stem cells as protective carriers that can transport therapeutic agents into tumors while helping shield those agents from the body’s immune system. Calidi’s technology platforms include NeuroNova, which is based on neural stem cells, and SuperNova, which uses engineered allogeneic stem cells. Its development programs have focused on potential treatments for solid tumors, including recurrent glioblastoma, and are intended to support the delivery of oncolytic viruses and other anti-cancer payloads directly to tumor sites. Founded in 2014 and headquartered in San Diego, California, Calidi Biotherapeutics became a publicly traded company through a business combination in 2023 and trades on the NYSE American under the symbol CLDI. The company’s programs remain in clinical development, and its research and potential commercial activities are focused on oncology applications.View Calidi Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
